KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$0.8.

  • Supernus Pharmaceuticals' EPS (Basic) fell 21428.57% to -$0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 13055.56%. This contributed to the annual value of $1.34 for FY2024, which is 660280.54% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' EPS (Basic) is -$0.8, which was down 21428.57% from $0.4 recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EPS (Basic) peaked at $0.7 during Q3 2024, and registered a low of -$0.8 during Q3 2025.
  • In the last 5 years, Supernus Pharmaceuticals' EPS (Basic) had a median value of $0.15 in 2022 and averaged $0.15.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 190000.0% in 2024, then crashed by 938094.12% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.05 in 2021, then skyrocketed by 840.0% to $0.47 in 2022, then plummeted by 95.74% to $0.02 in 2023, then skyrocketed by 1295.37% to $0.28 in 2024, then plummeted by 386.66% to -$0.8 in 2025.
  • Its EPS (Basic) stands at -$0.8 for Q3 2025, versus $0.4 for Q2 2025 and -$0.21 for Q1 2025.